Potentially new isobaric metabolite of fluvastatin observed by LC-MS/MS during incurred sample analysis
Marie-Pierre Taillon1, Cynthia Côté, Milton Furtado
1Algorithme Pharma Inc., 575 Armand-Frappier Blvd., Laval (Montréal), Quebec, H7V 4B3, Canada.
Background:
Fluvastatin (Lescol(®)) is a racemic mixture of two erythro stereoisomers and metabolizes into two threo stereoisomers. A method was developed to chromatographically separate fluvastatin from its threo isomers to support a bioequivalence study.
Results:
During incurred samples analysis, an additional peak sharing the same mass transition as fluvastatin was observed and interfered with fluvastatin's quantification. Consequently, the chromatographic conditions were modified in order to resolve fluvastatin and the interference. Extensive evaluations were performed to ensure that the interference is not a degradation product generated during sample processing.
Conclusion:
An isobaric compound of fluvastatin was discovered, which required chromatographic separation from fluvastatin to obtain a reliable bioanalytical method. The investigation performed suggests that the interference is produced in vivo and is a possible metabolite of fluvastatin.
More Related Videos
11:06Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia
Published on: April 7, 2023
14:42Liquid Chromatography Coupled to Refractive Index or Mass Spectrometric Detection for Metabolite Profiling in Lysate-based Cell-free Systems
Published on: September 23, 2021